Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Daratumumab + Dexamethasone + Lenalidomide & Multiple Myeloma (MM) / Plasmocytoma, the triplet Daratumumab + Dexamethasone + Lenalidomide (often abbreviated DRd or D‑Rd) is an approved regimen for multiple myeloma by both FDA and EMA; “plasmocytoma” is not listed separately but is encompassed under systemic multiple myeloma/plasma‑cell myeloma in these labels.
The randomized clinical phase III trial, identified as NCT02252172 (MAIA), demonstrated that the com…